Search

Your search keyword '"Awwad, Sara"' showing total 13 results
Start Over Author "Awwad, Sara"
13 results on '"Awwad, Sara"'

7. The impact of COVID-19 crisis on the testing process of the Primary Health Care Corporation (PHCC) Laboratories in state of Qatar

Author

Awwad, Sara Tuma and Abu-Madi, Marawan

Subjects
PHCC health centers, COVID-19, testing process, cross-sectional retrospective
Abstract

Introduction The global healthcare systems have been significantly impacted by the coronavirus COVID-19 pandemic. It was a public health emergency that affects many health care services, including primary health care and caused an extraordinary shift in the demands for patient care and clinical laboratory testing. Methods This is a cross-sectional retrospective study, data were collected from Primary Health Care Corporation (PHCC) Clinical Information System (CIS-Cerner), over the period of January 2019-December 2021. Data collection of the laboratory departments in the PHCC health centers were processed from six Health Centers, chosen randomly from different regions (Northern, Central and Western regions of Qatar). Two health centers, one converted to COVID-19 center and the other maintained ordinary operation health center were chosen from each region. COVID-19-impacted cases were treated at the COVID-19 HC, while the usual work was maintained at the ordinary operated HC. Results A total of 404,316 laboratory tests were analyzed from six PHCC centers; including 36.8% tests from Northern region, 38.3% from Central region, and 24.9% from Western region. Of those, 386,477 were Routine tests and 12,777 Short Turnaround (STAT) tests. A total of 5062 tests were excluded from the analysis due to missing data. We found a significant difference between the ordinary operated health centers (Leabaib, Al Thumama and Al Waab) and COVID-19 health centers (Umm Slal, Rawdat Alkhail and Muaither) with a statistically significant reduction in Turnaround time (TAT) for STAT Complete Blood Count (CBC) tests from 69.7% to 30.3% in the year 2020 (p

Published
2023

12. Ultrasound-based Accuro system versus traditional palpation technique for neuraxial anaesthesia: A systematic review and meta-analysis of randomised controlled trials

Author

Sharapi, Mahfouz, Afifi, Eslam, Al Mawla, Aya Mustafa, Yassin, Mazen Negmeldin Aly, Awwad, Sara Adel, and El-Samahy, Mohamed

Abstract

Introduction This review evaluates the efficacy and safety of Accuro, a handheld ultrasound device, compared to the palpation technique for neuraxial anaesthesia. Accuro provides real-time imaging guidance, potentially improving accuracy and efficiency.Methods A comprehensive search across six electronic databases identified randomised clinical trials comparing Accuro with palpation for neuraxial anaesthesia. Risk ratios or mean differences with 95% confidence intervals (CIs) were calculated using a random-effects model. Bias risk was evaluated using the Cochrane Risk of Bias tool.Results Five studies (n=369) met the inclusion criteria. Accuro showed a favourable risk ratio for first insertion success (1.44 [95% CI [1.01, 2.05], p=0.05]). It significantly reduced needle skin passes (MD −0.63; 95% CI [−1.05, −0.21]; p<0.01), but not needle redirection (MD −1.31; 95% CI [−2.71, 0.11]; p=0.07). Procedure time was shorter in palpation (MD 127.82; 95% CI [8.68, −246.97]; p=0.04). Four studies had a low risk of bias; one had some concerns.Conclusion Accuro can potentially improve success rates and reduce skin passes in neuraxial anaesthesia. Further trials with larger samples are needed, especially in patients with anticipated difficulties.

Published
2024
Full Text
View/download PDF

13. The efficacy of Veliparib in combination with chemotherapy in the treatment of lung cancer: systematic review and meta-analysis.

Author

Kashbour M, Alhadeethi A, Awwad S, Yassin M, Amin A, Abed M, Abdelmalik A, and Alabdallat YJ

Abstract

Objective: This meta-analysis aims to examine the effectiveness of veliparib, a poly ADP-ribose polymerase inhibitor, in combination with chemotherapy in treating bronchogenic carcinoma., Methods: PubMed, Cochrane, Scopus, and Web of Science were searched for eligible randomized controlled trials comparing veliparib plus chemotherapy to standard chemotherapy in adult lung cancer patients, until July 2023. The main outcomes were overall survival (OS) and progression-free survival (PFS)., Results: This meta-analysis included six studies encompassing 2,136 patients. Veliparib has a slight OS improvement over placebo, HR = 0.91, 95% CI [0.83 to 1.0], p  = 0.05. Veliparib offers more OS benefit in the subpopulation of non-small cell lung cancer (NSCLC) than small-cell lung cancer (SCLC), HR = 0.89, 95% CI [0.81,0.99], p  = 0.03 and HR = 1.00, 95% CI [0.79, 1.28], p  = 0.97, respectively. There was no significant PFS benefit between the two groups, HR = 0.92, 95% CI [0.81-1.01], p  = 0.08)., Conclusion: Veliparib has a marginal inclination for overall survival improvement, more so in NSCLC, with an acceptable safety profile. Our results merit the pursuit of better-powered trials to support further the extent of veliparib's effectiveness in lung cancer patients., Registration: PROSPERO (CRD42023453705).

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results